相关实验视频
Updated: Jun 18, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
形甲状腺癌的联合放射和化疗与单疗法:A SEER回顾性分析
Wenxin Zhang1, Hui Wang1, Weijian Li1
1Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, 300052, China.
与单一治疗相比,联合放射和化疗 (组合疗法) 并没有显著改善形甲状腺癌 (ATC) 患者的生存率. 需要进一步的研究来优化这种罕见癌症的治疗策略.
科学领域:
- 在瘤学瘤学.
- 甲状腺癌研究研究
背景情况:
- 无塑性甲状腺癌 (ATC) 是一种具有不良预后的侵袭性甲状腺癌.
- 对ATC的最佳治疗策略,特别是组合治疗与单一治疗的作用,仍然不清楚.
研究的目的:
- 为了评估治疗形甲状腺癌患者的生存结果,患者接受了联合辐射和化疗,而不是单一治疗.
- 为了确定组合疗法是否为ATC提供了比单一疗法治疗更有利的生存益处.
主要方法:
- 来自2010-2015年SEER数据库的516名ATC患者的回顾性分析.
- 卡普兰-梅尔方法,考克斯回归和倾向性得分匹配 (PSM) 用于评估生存率.
- 在治疗组之间比较整体存活率 (OS) 和癌症特异性存活率 (CSS).
主要成果:
- 整个队列的中位数OS为3个月;6个月和12个月的OS率分别为29%和13%.
- 多变量分析表明,与组合治疗相比,没有接受放射治疗或化疗的患者的生存结果更差.
- 然而,在PSM后,组合疗法与单一疗法 (单独化疗或单独放射疗法) 相比,没有显著改善OS或CSS.
结论:
- 对ATC的组合疗法没有比单一疗法提供显著的生存优势.
- 这些发现表明,目前的组合治疗方法可能不会超过单个治疗方式的好处.
- 需要进行进一步的前性研究,以开发更有效的,针对性治疗策略来治疗形甲状腺癌.
更多相关视频
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
03:55Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Survival Analysis
Tumor Immunotherapy